RegulatoryCompany release

Oncolytics reports roughly 15-month response durability for pelareorep plus atezolizumab in anal cancer

🇺🇸 Oncolytics Biotech Inc (ONCY) · Tue 27 Oct 2026

Updated Cohort 4 data from the GOBLET study show median duration of response of about 15 months in second-line or later squamous cell anal cancer, with median overall survival not yet reached.

Oncolytics Biotech has released updated results from Cohort 4 of its Phase 1/2 GOBLET study, which is testing pelareorep in combination with atezolizumab in patients with squamous cell anal cancer who have received at least one prior line of therapy. The company announced the data on 27 October 2026.

According to the company, the median duration of response is approximately 15 months, and all patients who responded have survived beyond 12 months. Median overall survival has not yet been reached. The summary available does not give patient numbers, response rates or confidence intervals, so the robustness of these figures cannot be assessed from it.

Oncolytics points to the FDA Fast Track Designation it holds for the programme and to recent interactions with the agency as support for exploring further studies. These would aim at accelerated or full approval, which the company says remains subject to FDA agreement. It also names a possible expansion into HPV-driven head and neck cancer.

For context, Fast Track Designation is intended to facilitate development and review of drugs for serious conditions with unmet need. It does not guarantee approval or specify the evidence the agency will require.

What it means for your team

  • The data come from a Phase 1/2 study; any regulatory path to accelerated or full approval depends on FDA agreement on further trials, which has not yet been announced.
  • Full details such as cohort size, response rate and follow-up are needed before the durability claim can be benchmarked against existing second-line options.
  • Teams tracking oncology pipelines should note the stated interest in HPV-driven head and neck cancer as a potential future indication, though no study has been described.

Company's press release (SEC filing): Oncolytics Biotech Inc ↗

Article written by VigiEye from the official source (Oncolytics Biotech Inc). Claims are the company's own. AI-assisted; check the source before acting.

More Regulatory All →